Representative layout and images of focus reduction neutralization assay with P4A2 mAb.

Parray, Hilal Ahmad; Narayanan, Naveen; Garg, Sonal; Rizvi, Zaigham Abbas; Shrivastava, Tripti; Kushwaha, Sachin; Singh, Janmejay; Murugavelu, Praveenkumar; Anantharaj, Anbalagan; Mehdi, Farha; Raj, Nisha; Singh, Shivam; Dandotiya, Jyotsna; Lukose, Asha; Jamwal, Deepti; Kumar, Sandeep; Chiranjivi, Adarsh K.; Dhyani, Samridhi; Mishra, Nitesh; Kumar, Sanjeev; Jakhar, Kamini; Sonar, Sudipta; Panchal, Anil Kumar; Tripathy, Manas Ranjan; Chowdhury, Shirlie Roy; Ahmed, Shubbir; Samal, Sweety; Mani, Shailendra; Bhattacharyya, Sankar; Das, Supratik; Sinha, Subrata; Luthra, Kalpana; Batra, Gaurav; Sehgal, Devinder; Medigeshi, Guruprasad R.; Sharma, Chandresh; Awasthi, Amit; Garg, Pramod Kumar; Nair, Deepak T.; Kumar, Rajesh

doi:10.1371/journal.ppat.1010994.s008

ppat.1010994.s008.pdf (2.39 MB)

Representative layout and images of focus reduction neutralization assay with P4A2 mAb.

journal contribution

posted on 2022-12-12, 18:39 authored by Hilal Ahmad Parray, Naveen Narayanan, Sonal Garg, Zaigham Abbas Rizvi, Tripti Shrivastava, Sachin Kushwaha, Janmejay Singh, Praveenkumar Murugavelu, Anbalagan Anantharaj, Farha Mehdi, Nisha Raj, Shivam Singh, Jyotsna Dandotiya, Asha Lukose, Deepti Jamwal, Sandeep Kumar, Adarsh K. Chiranjivi, Samridhi Dhyani, Nitesh Mishra, Sanjeev Kumar, Kamini Jakhar, Sudipta Sonar, Anil Kumar Panchal, Manas Ranjan Tripathy, Shirlie Roy Chowdhury, Shubbir Ahmed, Sweety Samal, Shailendra Mani, Sankar Bhattacharyya, Supratik Das, Subrata Sinha, Kalpana Luthra, Gaurav Batra, Devinder Sehgal, Guruprasad R. Medigeshi, Chandresh Sharma, Amit Awasthi, Pramod Kumar Garg, Deepak T. Nair, Rajesh Kumar

(A) SARS-CoV-2 neutralizing antibodies were used as the positive control [two-fold dilution series starting at 1:20 and ending at 1:640 (highlighted in green)]. Pre-defined virus dilution (virus only control; wells 7 through 11 in rows A and B to get at least 60–200 FFU/well) and only medium (no virus control; added in well 12 in rows A and B) served as the control. P4A2 (rows C and D), Sotrovimab (rows E and F) and CR30322 (rows G and H) as two-fold serial dilutions were used in the experiment. The antibody neutralization assays against SARS-CoV-2 Delta variant (B.1.617.2) (B) and Omicron variant (B.1.1.529) (C) was done similarly.

(PDF)

Representative layout and images of focus reduction neutralization assay with P4A2 mAb.

History

Usage metrics

Categories

Keywords

Licence

Exports